Archive

Effect of an eight week dietary intervention of pecans on cardiometabolic parameters and serum cytokines in individuals with obesity or overweight: a preliminary study.

McCormick, S., T. Solberg, J. Scoles, C. Mayne, M. Morgan-Bathke, 2026. Effect of an eight week dietary intervention of pecans on cardiometabolic parameters and serum cytokines in individuals with obesity or overweight: a preliminary study. Curr Issues Mol Biol. 48(8):798. doi:10.3390/cimb48080798.

Obesity is a major health concern within the United States. Previous studies have shown that a diet high in monounsaturated fatty acids (MUFA) may help combat metabolic disease by improving cardiometabolic and inflammatory status. Pecans have high MUFA content and the highest antioxidant capacity of any nut. The aim of this preliminary study is to determine if a diet supplemented with 1.5 ounces of pecans daily for eight weeks could improve blood glucose, lipid panel, inflammatory markers, and body composition in individuals with overweight and obesity as compared to a control group who maintained their normal diet. Post-intervention measurements showed no significant difference from baseline values for either the experimental or the control group. Data acquired using the Vioscreen Food Frequency Questionnaire found negative correlations were present between LDL cholesterol and dietary intake of iron, selenium, zinc, MUFA, polyunsaturated fatty acids, saturated fatty acids, and dietary cholesterol. Furthermore, there were negative correlations determined between fasting blood glucose and dietary intake of magnesium, MUFA, and SFA. Regarding inflammatory markers, no detectable levels of IL-10 nor TNF-α were found in the majority of samples. IL-6 was detectable in all samples but showed no statistical difference between any of the groups in the study. Thus, an intervention of 1.5 oz of pecans for eight weeks did not significantly change measured metabolic parameters nor levels of serum IL-6. However, due to the sample size limitations of this hypothesis-generating preliminary study, further research is needed. Further studies should include a longer intervention period, a larger cohort, and potentially a larger dosage of pecans to increase the amount of MUFA in the diet to determine if such interventions may influence cardiometabolic and inflammatory parameters.

The effect of pecan consumption on cardiometabolic risk factors: a systematic review and meta-analysis of randomized controlled trials.

Zhang, Z., M.H. Sohouli, 2026. The effect of pecan consumption on cardiometabolic risk factors: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 18(1):180. doi: 10.1186/s13098-026-02212-1.

Background: Pecans are rich in monounsaturated fats, phytosterols, fiber, and polyphenols, suggesting potential cardiometabolic benefits. However, evidence from randomized controlled trials (RCTs) remains inconsistent, and no prior synthesis has comprehensively quantified their effects on major metabolic risk factors. Therefore, we aimed to systematically evaluate the effects of pecan consumption on cardiometabolic outcomes in adults using data from RCTs. Methods: A systematic search of PubMed, Scopus, Web of Science, Embase, and Cochrane CENTRAL was conducted through November 2025. Eligible studies were RCTs assessing pecan consumption versus control diets and reporting changes in glycemic indices, anthropometric measures, lipid profiles, or blood pressure. Random-effects models were used to calculate weighted mean differences (WMDs). Results: A total of 10 randomized controlled trials were included. Pecan consumption significantly reduced total cholesterol (7 studies; WMD: – 8.49 mg/dL; 95% CI: – 12.61 to – 4.37; I²=0.0%), LDL-cholesterol (7 studies; WMD: – 7.42 mg/dL; 95% CI: – 10.83 to – 4.01; I²=0.0%), and triglycerides (7 studies; WMD: – 14.06 mg/dL; 95% CI: – 22.37 to – 5.75; I²=0.0%). Little evidence of an effect was observed for HDL-cholesterol (7 studies; I²=0.0%), fasting glucose (4 studies; I²=71.2%), insulin (4 studies; I²=44.6%), HOMA-IR (3 studies; I²=12.8%), body weight (4 studies; I²=0.0%), BMI (3 studies; I²=0.0%), waist circumference (4 studies; I²=0.0%), systolic blood pressure (4 studies; I²=88.8%), or diastolic blood pressure (4 studies; I²=89.6%). Subgroup analyses showed consistent LDL-C reductions across all doses and durations, whereas triglyceride reductions were evident only in interventions > 4 weeks. Sensitivity analyses confirmed the robustness of findings, and no publication bias was detected. Conclusions: Pecan consumption was associated with improvements in total cholesterol, LDL-cholesterol, and triglycerides but does not significantly influence glycemic control, adiposity, or blood pressure. Pecans represent a beneficial lipid-modifying component of cardioprotective dietary patterns. Larger, long-term RCTs in high-risk populations are warranted.

MicroRNAs, nut consumption, cardiovascular risk factors, and coronary artery disease: A narrative review.

Stein, E., G.B.S. Duarte, A.C. Bersch-Ferreira, C. Weschenfelder, M.F. Figueiro, M.M. Rogero, E.O. de Abreu-Silva, A. Marcadenti, 2026. MicroRNAs, nut consumption, cardiovascular risk factors, and coronary artery disease: A narrative review. Nutr Rev. 84(11):2291-2305.

Coronary artery disease (CAD) remains the leading cause of death worldwide and has a multifactorial etiology involving genetic, metabolic, and behavioral factors. Hypertension and dyslipidemia contribute significantly to atherosclerosis progression, and these conditions may be influenced by microRNAs (miRNAs), which act as post-transcriptional gene expression regulators. In turn, miRNA expression can be modulated by nutrient-dense dietary patterns or cardioprotective foods, such as nuts. Despite growing interest in miRNAs and cardiovascular disease (CVD) risk, few reviews have specifically addressed the unique role of nuts in modulating miRNA expression, particularly regarding gaps in secondary prevention of CAD. This study summarizes the main miRNAs associated with blood pressure, lipid metabolism, and atherosclerotic disease, as well as the current evidence on how nut consumption influences their expression. Several miRNAs, including miR-1, miR-21, the miR-29 family, miR-30a/b, miR-133, miR-143, miR-145, and miR-221/222, are dysregulated in hypertension and associated with circadian blood pressure patterns, left ventricular hypertrophy, and antihypertensive response. Others, such as miR-122, miR-33a/b, miR-148a, miR-483-5p, and miR-145, are linked to lipid metabolism, plaque instability, and ischemic outcomes. Nut-rich diets, particularly the Mediterranean diet, seem to modulate miRNAs associated with pathways involved in lipid homeostasis, endothelial function, and inflammation. Data from clinical trials conducted in primary CVD prevention setting have shown changes in circulating miRNAs in response to diets rich in nuts. Additional studies with Brazil nuts, pistachios, almonds, and walnuts supplementation also reported modulation of miRNAs involved in lipid homeostasis, inflammation, and insulin resistance, including significant changes in expression of miR-15a, miR-21, miR-328, miR-454-3p, miR-29a-3p, miR-192, miR-330-3p, miR-32-5p, miR-29b-3p, and miR-551a. Nonetheless, it appears no studies have yet evaluated the effect of nut supplementation on miRNAs in secondary prevention of CAD. Although the evidence is promising, more research is needed to clarify the impact of nut consumption on miRNA modulation, particularly in secondary prevention of CVD.

Nut consumption and risk of cardiovascular disease events and all-cause mortality: A systematic review and dose-response meta-analysis of prospective cohort studies.

Liu, M., M. Wang, X. Fu, X. He, M. Wang, Y. Su, G. Liu, F. Hu, M. Zhang, Y. Zhao, D. Hu, 2026. Nut consumption and risk of cardiovascular disease events and all-cause mortality: A systematic review and dose-response meta-analysis of prospective cohort studies. Arch Cardiovasc Dis. 119(3):216-232. doi: 10.1016/j.acvd.2025.08.010.

Background: Evidence for the effects of nut consumption on cardiovascular disease (CVD) events and all-cause mortality has been reported inconsistently. Aims: To assess the associations between nut consumption and CVD events and all-cause mortality. Methods: We searched the Web of Science, Embase and PubMed up until 24 October 2023. In order to compute relative risks (RRs) and 95% confidence intervals (CIs), random-effects models were employed. Restricted cubic splines were performed to explore potential linear or non-linear associations. Heterogeneity was assessed (Cochran Q statistic) and quantified (I2-statistic). NutriGrade assessed the certainty of the evidence. Results: Thirty-three publications (63 studies) were included. Comparisons between individuals with the highest versus lowest intake of nuts resulted in RRs (95% CIs) for coronary heart disease (CHD), stroke, CVD, CVD mortality and all-cause mortality of 0.81 (0.75-0.87), 0.91 (0.84-0.99), 0.86 (0.82-0.91), 0.74 (0.70-0.78) and 0.77 (0.73-0.81), respectively. With per 28-g increases in weekly nut intake, the RRs (95% CIs) for CHD, stroke, CVD, CVD mortality and all-cause mortality were 0.96 (0.95-0.97), 0.99 (0.97-1.01), 0.98 (0.97-0.99), 0.90 (0.86-0.94) and 0.92 (0.90-0.94), respectively. Nut intake was linearly associated with incidence of stroke (Pnon-linearity=0.691), CVD (Pnon-linearity=0.101) and CVD mortality (Pnon-linearity=0.069) and non-linearly associated with CHD (Pnon-linearity<0.05) and all-cause mortality (Pnon-linearity<0.001). Conclusions: This systematic review and meta-analysis revealed an association between nut consumption and reduced risk of CVD and all-cause mortality. It highlighted the importance of nuts as a dietary supplement in the primary prevention of CVD and all-cause mortality.